GC1118
GC1118 (GC-1118A) is a fully human anti-EGFR monoclonal antibody with binding affinity of 0.16 nM (KD) to EGFR. GC1118 displays potent inhibitory effects on high- and low-affinity EGFR ligand-induced signaling. GC1118 shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells. GC1118 can reach the tumor by crossing both BBB (blood-brain barrier) and BTB (brain-tumor barrier) and shows superior anti-tumor effects in various mice xenograft models. GC1118 can be used for the researches of cancer, such as colorectal cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.22%
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Human
EGFR
GC1118 (GC-1118A) (1 μg/mL, 24-120 h) shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells[1][4].
GC1118 (100 µM, 6 days) suppresses cell growth in PDCs of G096 and G022[2].
GC1118 (0.1-50 μg/mL, 2 h) blocks EGFR high- and low-affinity ligand-induced EGFR signaling in HCT8 cells[3].
GC1118 (0.005-100 μg/mL, 3 days) inhibits high- and low-affinity ligand-induced proliferation in HCT8 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SNU-1, SNU-5, SNU-16, SNU-216, SNU-484, SNU-601, SNU-620, SNU-638, SNU-668, SNU-719, AGS, MKN-45 and NCI-N87 cells
-
Concentration:0, 0.001, 0.01, 0.1, 1, 10, 100 and 1000 µg/ mL
-
Incubation Time:72 h
-
Result:Suppressed cell growth, particularly in the MKN-45 cell line.
-
Cell Line:SNU-484, SNU-601, SNU-719 and MKN-45 cells
-
Concentration:1 µg/mL
-
Incubation Time:24, 72, 120 h
-
Result:Showed more obviously anti-growth inhibitory effect in KRAS wild-type cell lines, SNU-719 and MKN-45, but also in KRAS mutant SNU-601 cells.
-
Cell Line:HCT8 cells
-
Concentration:0.1, 0.5, 5 and 50 μg/mL
-
Incubation Time:2 h, stimulated with EGFR ligands (250 ng/mL EGF, HB-EGF, BTC, and TGF-α; 300 ng/mL AREG; 500 ng/mL EREG)
-
Result:Inhibited the high- and low-affinity ligand-induced Y1068 phosphorylation, Akt and Erk levels.
GC1118 (GC-1118A) (1 mg/kg, i.p., twice a week for 5 weeks) significantly suppresses xenograft tumor growth in AGS xenograft mice models[1].
GC1118 (50 mg/kg, i.p., twice a week) shows superior antitumor activity in patient-derived GBM xenograft models[2].
GC1118 (1 mg/mouse, i.p., twice a week for 5 weeks) significantly suppresses the tumor growth in HCT8, Lovo, HCT15, LS174T, LS513, and SW48 xenograft mice models[3].
GC1118 (1 mg/mouse, i.p., twice a week for 52 days) had moderate antitumor effects in CRC-024T patient-derived xenograft mice models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:AGS xenograft mice models (athymic nude mice, female, 6 weeks, tumor volume of 200 mm3)[1]
-
Dosage:1 mg/kg
-
Administration:Intraperitoneally injection, twice a week for 5 weeks
-
Result:Showed a significant suppression of the tumor growth.
-
Animal Model:Patient-derived GBM xenograft models (BALB/c nude mice, female, 6-8 weeks, tumor volume of 150-200 mm3)[2]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneal injection; twice a week until euthanasia
-
Result:Exerted anti-tumor effects in eight PDXs (G022, G677, B802, G608, G542, G096, G698, and G500).
Showed significantly better survival outcome than the control group.
Showed a significant amount accumulated in the tumor core.
Significantly increased tumor cell apoptosis and reduced microvascular density (MVD).
-
Animal Model:HCT8, Lovo, HCT15, LS174T, LS513, and SW48 xenograft mice models (athymic nude mice, 7-8 weeks, tumor volume of 200 mm3)[3]
-
Dosage:1 mg/mouse
-
Administration:Intraperitoneally injection, twice a week for 5 weeks
-
Result:Significantly suppressed the tumor growth.
-
Animal Model:CRC-024T patient-derived xenograft mice models (BALB/c-nude mice, female, 6-8 weeks, tumor volume of 200-250 mm3)[4]
-
Dosage:1 mg/mouse
-
Administration:Intraperitoneally injection, twice a week for 52 days
-
Result:Had moderate antitumor effects and no reduction in body weight.
Downregulated the levels of AKT and ERK1/2.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
P00533-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized EGFR-his can bind GC1118. The EC50 for this effect is 9.234 ng/mL.
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
GC-1118A
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (267 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. ark JE, et al. GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. Gastric Cancer. 2019 Sep;22(5):932-940. [Content Brief]
[2]. Lee K, et al. Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts. Cancers (Basel). 2020 Oct 31;12(11):3210. [Content Brief]
[3]. Lim Y, et al. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands. Mol Cancer Ther. 2016 Feb;15(2):251-63. [Content Brief]
[4]. Lee HW, et al. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts. Int J Mol Sci. 2019 Nov 24;20(23):5894. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GC1118 Related Classifications
HY-P991571 Related Classifications
Powered by Bioz